Lipodystrophy Syndrome, HIV

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Lipodystrophy Syndrome, HIV trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT03087253

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States. These rare disord…

United States, Brazil, Turkey (Türkiye)500 participantsStarted 2018-02-27

All recent trials (98 shown)

CompletedPhase 4

NCT03226821

Body Composition and Adipose Tissue in HIV

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in p…

United States5 participantsStarted 2018-02-07

Treatment: Tesamorelin

CompletedPhase 4

NCT04904406

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Randomized controlled parallel open-label study in people living with HIV and at least 6 month of treatment with dolutegravir/abacavir/lamivudine prior to inclu…

Denmark81 participantsStarted 2020-10-22

Treatment: Dolutegravir / Lamivudine Oral Tablet

Lipodystrophy Syndrome, HIV

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

All recent trials (98 shown)

Body Composition and Adipose Tissue in HIV

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

All recent trials (98 shown)

Body Composition and Adipose Tissue in HIV

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

The Visceral Adiposity Measurement and Observation Study

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Growth Hormone Dynamics and Cardiac Steatosis in HIV

Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

HIV Fat Redistribution and the Evaluation of Brown Fat

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

Mechanisms of Lipodystrophy in HIV-Infected Pateints

Therapeutic Approaches to HAART-Induced Lipodystrophy

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

Eplerenone in HIV Associated Abdominal Fat Accumulation

Evaluation of Albuminuria HIV-Infected Patients